Frequently Asked Questions

Pharmacies across Texas are facing heightened enforcement and increased scrutiny by the Texas Board of Pharmacy (“BOP”). In recent months, aggressive investigators have conducted surprise visits to pharmacies. In some cases, the BOP has gone so far as to ask pharmacists to surrender their license on the spot.

If you are targeted by the BOP or other agency, it is critical to not say or do anything unless you fully understand the implications. In addition, it is always advisable to have a witness so investigators cannot twist statements to support their position.

Like PBM audits, your statements can be recorded and used against you. Therefore, before the underlying facts and circumstances become clear, it is advisable to not take a position on anything absent legal representation.

Likewise, get prepared. Don’t wait for an investigation to arise before you take steps to protect yourself. If you are aware of areas of potential concern, whatever they may be, let us help you address them.

In a highly regulated industry like healthcare, there are often grey areas around compliance. Although these areas present opportunities, some degree of risk comes with everything.

If and when someone disagrees with the approach your business has taken, all processes involved will be heavily scrutinized and tested. Your decision-making and compliance efforts likewise will be second-guessed.

In short, act proactively to insulate your livelihood from attack, whether that be from the Texas Board or any other regulator. And if you are already dealing with an investigation or discrepant PBM audit that could be referred to regulators, don't wait to take defensive action. Schedule a free consultation now.

MORE ARTICLES BY CATEGORY

Get a Free Case REVIEW

100% Confidential & Secure. Your details are safe with us.

We'll speak soon!

In the meantime, why not find out more about us or visit our blog.

Alternatively, give us a call at (800) 345 - 4125

Oops! Something went wrong while submitting the form.

HLA's Diana Yastrovskaya Featured in PBM Discussion for WJAC

The feature underscores HLA’s mission to elevate thought leadership within the healthcare space and provide trusted expertise on issues that directly impact patients, providers, and policymakers.

Read More >>

By Appointment Only: How DME Suppliers Can Prevent Unexpected DME License Revocations

DME suppliers can prevent unexpected and costly license revocations by strategically applying with a "By Appointment Only" designation. This article explores the common compliance trap of failing unannounced site visits due to conflicts between standard pharmacy operating hours and Medicare's "posted hours" requirement for DME suppliers. "By Appointment Only" status is a crucial safeguard, which suppliers can take to implement to protect their DME billing privileges.

Read More >>

Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing

Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.

Read More >>

9th Circuit’s Landmark EKRA Ruling—What Providers Should Know

On July 11, 2025, the 9th Circuit upheld a laboratory operator’s convictions for violating EKRA by paying marketing agents to mislead providers into providing patient referrals for medically unnecessary blood tests. In this article, we analyze the 9th Circuit’s ruling and what it means for the future of EKRA enforcement.

Read More >>